

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. or both. In this environment, spikes in hospitalisations are rarer due to a combination of pre-existing immunity and selection of less pathogenic SARS-CoV-2 variants, such as omicron. Yet, we cannot dismiss the fact that highly pathogenic or transmissible variants might develop. In low-income and middle-income countries where fewer people are vaccinated, SARS-CoV-2 will diversify more rapidly.

The global community must keep pushing for equity in access to COVID-19 vaccines and treatments in countries with low immunisation rates. Preventing the spread of SARS-CoV-2 will obstruct the virus from adapting whilst more directed data-driven prevention measures are implemented in highly immunised countries. With advancing SARS-CoV-2 knowledge—especially from large studies like that of Nyberg and colleagues—together with new and developing vaccines, treatments, and therapeutics, we might be on the precipice of more targeted, preventive measures that allow us to avoid blanket, highly restrictive policies that have harmful costs to the economy, society, and public health.

We declare no competing interests.

*Lori Ann Post, Ramon Lorenzo-Redondo lori.post@northwestern.edu

Department of Emergency Medicine (LAP), Buehler Center for Health Policy & Economics, Institute for Global Health (LAP), Division of Infectious Diseases, Department of Medicine, (RL-R), and Center for Pathogen Genomic and Microbial Evolution, Institute for Global Health (RL-R), Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA

- Tangcharoensathien V, Bassett MT, Meng Q, Mills A. Are overwhelmed health systems an inevitable consequence of covid-19? Experiences from China, Thailand, and New York State. BMJ 2021; 372: n83.
- 2 Dhawan M, Priyanka AS, Choudhary OP. Vaccine inequity and hesitancy: dual factors in the emergence of novel SARS-CoV-2 variants. Ann Med Surg 2022; 73: 103186.
- 3 Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 omicron variant in southern Africa. *Nature* 2022; published online Jan 7. https://doi.org/10.1038/s41586-022-04411-y.
- 4 Andrews N, Stowe J, Kirsebom F, et al. Effectiveness of COVID-19 vaccines against the omicron (B. 1.1. 529) variant of concern. *medRxiv* 2021; published online Dec 14. https://doi.org/10.1101/2021.12.14.21267615 (preprint).
- 5 Lundberg AL, Lorenzo-Redondo R, Ozer EA, et al. Has omicron changed the evolution of the pandemic? JMIR Public Health Surveill 2022; 8: e35763.
- Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARSCoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. *Lancet* 2022; published online March 16. https://doi.org/10.1016/S0140-6736(22)00462-7.
- 7 Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet 2022; 399: 437–46.
- 8 Bager P, Wohlfahrt J, Bhatt S, et al. Reduced risk of hospitalisation associated with infection with SARS-CoV-2 omicron relative to delta: a Danish cohort study. SSRN 2022; published online Jan 14. https://ssrn.com/ abstract=4008930 (preprint).
- Veneti L, Bøås H, Kristoffersen AB, et al. Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 omicron BA. 1 variant compared with the delta variant, Norway, December 2021 to January 2022. Eurosurveillance 2022; 27: 2200077.
- 10 Sheikh A, Kerr S, Woolhouse M, McMenamin J, Robertson C. Severity of omicron variant of concern and vaccine effectiveness against symptomatic disease: national cohort with nested test negative design study in Scotland. Edinburgh Research Explorer 2021; published online Dec 22. https://www. pure.ed.ac.uk/ws/portalfiles/portal/245818096/Severity_of_Omicron_ variant_of_concern_and_vaccine_effectiveness_against_symptomatic_ disease.pdf (preprint).
- 11 Townsend JP, Hassler HB, Wang Z, et al. The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study. Lancet Microbe 2021: 2: e666–75.
- 12 Centers for Disease Control and Prevention. COVID data tracker. https:// covid.cdc.gov/covid-data-tracker/#new-hospital-admissions (accessed March 11, 2022).

DNA vaccines join the fight against COVID-19



As of March, 2022, just over 1 year has passed since the authorisation of first-generation vaccines against COVID-19. Since then, almost 10 billion doses of COVID-19 vaccines have been administered globally.¹ Although the delivery of this number of vaccines is a remarkable achievement, there is still a disparity in vaccine equity, access, and affordability between highincome and low-income countries. According to the Global Dashboard for Vaccine Equity (established by the UN Development Programme, WHO, and the University of Oxford), as of Jan 18, 2022, approximately 67.6% of people in high-income countries have had at least one dose, compared with only approximately 11.36% of people in low-income countries.² This inequity has major negative implications for global pandemic control; thus, there is an imperative to develop more affordable, scalable, and easily distributable vaccines.

In the current landscape of mRNA, viral vector, and inactivated COVID-19 vaccines, one modality that has been largely under-represented is DNA vaccines. In *The Lancet*, Akash Khobragade and colleagues³ report an interim analysis of a phase 3, randomised, double-blind, placebo-controlled study of a DNA vaccine, ZyCoV-D, against COVID-19. The vaccine contains a 2 mg dose of a DNA plasmid (pVAX-1) expressing the Wuhan Hu-1 spike antigen of SARS-CoV-2 and an IgE signal peptide, which is delivered intradermally using a needle-free injection system. Participants received three doses of vaccine or placebo at 28-day intervals. The primary outcome of this study was the number



of participants with first occurrence of symptomatic COVID-19, as determined by a symptomatic RT-PCR test 28 days after the third dose, until the targeted number of 158 cases was achieved. Between Jan 16 and June 23, 2021, 27703 participants (aged >12 years) were randomly assigned (1:1) to receive ZyCoV-D (n=13851) or placebo (n=13852), and 81 cases were eligible for the interim primary efficacy endpoint as per protocol, which yielded a vaccine efficacy of 66.6% (20 cases in the ZyCoV-D group and 61 in the placebo group). There was full protection against more severe disease and death. It is important to keep in mind that this study was done during a surge of the B.1.617.2 (delta) variant in India, and the study population was predominantly male (18592 [67.11%] male and 9111 [32.89%] female), with no ethnicity data reported. Furthermore, the efficacy analysis was not stratified for age. Age is a known determinant of both COVID-19 outcomes and vaccine effectiveness. Finally, the efficacy analysis was only performed after the third dose, limiting insight into the effect of the first and second doses-this is useful information where incomplete vaccination could occur.

The vaccine was found to be safe, with approximately equivalent prevalence of solicited adverse events between the ZyCoV-D (n=623) and placebo (n=620) groups. The authors state that the safety profile of ZyCoV-D is comparable to another DNA-based vaccine in development.⁴ Notably, ZyCoV-D was found to be stable at room temperature (25°C) for 2 months in initial studies, although it was stored at 2–8°C for this study. Based on the safety, immunogenicity, and efficacy findings from the phase 3 trial, ZyCoV-D has been granted Emergency Use Authorisation in India: a landmark milestone for DNA vaccines with potential to further contribute to the COVID-19 vaccine diversity and worldwide supply.

Despite decades of research and development of DNA vaccines, including at least eight candidates currently in clinical trials for COVID-19,⁵ they have had limited success. One of the main challenges for DNA vaccines is the delivery: mRNA vaccines need to cross only one membrane to reach their site of action (cytoplasm), whereas DNA vaccines need to cross the cytoplasm and the nuclear membrane. Because of this difference, the lipid nanoparticles that effectively deliver mRNA do not work as well for DNA. Historically, DNA vaccines

have required a physical method of delivery such as electroporation, or the needle-free injection system used in this study.⁶⁻⁸ Although these physical devices appear to be effective—as shown in this study—they pose a potential challenge for widespread use and scaleup. The device used in Khobragade and colleagues' study³ is small and portable (<50 g) and consists of an injector, syringe, and filling adapter. However, widespread administration of ZyCoV-D will be limited not only by production and availability of the DNA, but also the injection device, which is vulnerable to global manufacturing disruptions. If these delivery system challenges can be overcome then the amenable storage conditions, efficacy against COVID-19 (including the delta strain), and low cost (<US\$10) have poised ZyCoV-D to be another global solution in our fight against SARS-CoV-2, and might act as a catalyst for DNA-based vaccines against other diseases, such as tuberculosis and HIV-1, especially in areas that have restricted access and affordability.

AKB is a co-founder and reports holding shares in VaxEquity, a for-profit company that aims to develop self-amplifying RNA vaccines for infectious diseases, but is not currently actively involved in the company. VaxEquity does not produce DNA vaccines. L-GB has received honoraria from Gilead Sciences and Merck for advisory work in HIV prevention.

*Anna K Blakney, Linda-Gail Bekker anna.blakney@msl.ubc.ca

University of British Columbia, Michael Smith Laboratories, Vancouver, BC V6SOK3, Canada (AKB); The Desmond Tutu HIV Centre, University of Cape Town, Institute of Infectious Disease and Molecular Medicine, Cape Town, South Africa (L-GB)

- I Our World in Data. Coronavirus (COVID-19) vaccinations. 2022. https:// ourworldindata.org/covid-vaccinations?country=OWID_WRL (accessed Jan 18, 2022).
- 2 UN Development Programme. Vaccine access. https://data.undp.org/ vaccine-equity/accessibility/ (accessed Jan 18, 2022).
- 3 Khobragade A, Bhate S, Ramaiah V, et al. Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. *Lancet* 2022; **399**: 1313–21.
- 4 Tebas P, Yang S, Boyer JD, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, phase 1 clinical trial. EClinicalMedicine 2021; 31: 100689.
- 5 Sheridan C. First COVID-19 DNA vaccine approved, others in hot pursuit. Nat Biotechnol 2021; 39: 1479–82.
- 6 Lee J, Arun Kumar S, Jhan YY, Bishop CJ. Engineering DNA vaccines against infectious diseases. Acta Biomaterialia 2018; 80: 31–47.
- 7 Modjarrad K, Roberts CC, Mills KT, et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. *Lancet Infect Dis* 2019; 19: 1013–22.
- 8 Gaudinski MR, Houser KV, Morabito KM, et al. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. *Lancet* 2018; 391: 552–62.